Reaction Details |
| Report a problem with these data |
Target | Gastrin/cholecystokinin type B receptor |
---|
Ligand | BDBM50049785 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_47830 (CHEMBL662572) |
---|
IC50 | 0.3±n/a nM |
---|
Citation | Castro, JL; Ball, RG; Broughton, HB; Russell, MG; Rathbone, D; Watt, AP; Baker, R; Chapman, KL; Fletcher, AE; Patel, S; Smith, AJ; Marshall, GR; Ryecroft, W; Matassa, VG Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas. J Med Chem39:842-9 (1996) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Gastrin/cholecystokinin type B receptor |
---|
Name: | Gastrin/cholecystokinin type B receptor |
Synonyms: | CCK-2 receptor | CCK-B receptor | CCK-BR | CCKBR | CCKRB | Cholecystokinin A | Cholecystokinin receptor | Cholecystokinin-2 Receptor | GASR_HUMAN | Gastrin/cholecystokinin type B receptor |
Type: | G Protein-Coupled Receptor (GPCR) |
Mol. Mass.: | 48445.79 |
Organism: | Homo sapiens (Human) |
Description: | Stable expression of human CCK-2 receptors in HEK 293 cells. |
Residue: | 447 |
Sequence: | MELLKLNRSVQGTGPGPGASLCRPGAPLLNSSSVGNLSCEPPRIRGAGTRELELAIRITL
YAVIFLMSVGGNMLIIVVLGLSRRLRTVTNAFLLSLAVSDLLLAVACMPFTLLPNLMGTF
IFGTVICKAVSYLMGVSVSVSTLSLVAIALERYSAICRPLQARVWQTRSHAARVIVATWL
LSGLLMVPYPVYTVVQPVGPRVLQCVHRWPSARVRQTWSVLLLLLLFFIPGVVMAVAYGL
ISRELYLGLRFDGDSDSDSQSRVRNQGGLPGAVHQNGRCRPETGAVGEDSDGCYVQLPRS
RPALELTALTAPGPGSGSRPTQAKLLAKKRVVRMLLVIVVLFFLCWLPVYSANTWRAFDG
PGAHRALSGAPISFIHLLSYASACVNPLVYCFMHRRFRQACLETCARCCPRPPRARPRAL
PDEDPPTPSIASLSRLSYTTISTLGPG
|
|
|
BDBM50049785 |
---|
n/a |
---|
Name | BDBM50049785 |
Synonyms: | 1-((R)-5-Cyclohexyl-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-{4-methyl-3-[methyl-(1H-tetrazol-5-yl)-amino]-phenyl}-urea | CHEMBL168253 |
Type | Small organic molecule |
Emp. Form. | C26H31N9O2 |
Mol. Mass. | 501.5834 |
SMILES | CN(c1nnn[nH]1)c1cc(NC(=O)N[C@@H]2N=C(C3CCCCC3)c3ccccc3N(C)C2=O)ccc1C |t:16| |
Structure |
|